rs17228212 — SMAD3

SMAD3 rs17228212 — TGF-Beta Signaling and Vascular Disease Risk

The SMAD3 gene encodes a central intracellular mediator of transforming growth factor-beta (TGF-β) signaling¹¹ transforming growth factor-beta (TGF-β) signaling
a pathway controlling cell growth, differentiation, and fibrosis in virtually every tissue, including the arterial wall. Within the vasculature, SMAD3 governs vascular smooth muscle cell (VSMC) behavior²² vascular smooth muscle cell (VSMC) behavior
whether smooth muscle cells remain quiescent in a healthy vessel wall or shift toward a proliferative, inflammatory phenotype that promotes plaque growth. The intronic variant rs17228212 at chromosome 15q22.33 was first identified in 2007 as a genome-wide significant locus for coronary artery disease³³ genome-wide significant locus for coronary artery disease
combined analysis of the Wellcome Trust Case Control Consortium and German Myocardial Infarction Family Study, but subsequent studies have produced complex and sometimes conflicting results, making it one of the more nuanced CAD-associated variants in the database.

The Mechanism

SMAD3 functions as the primary intracellular messenger when TGF-β binds its receptor complex on the cell surface. After receptor activation, SMAD3 is phosphorylated, complexes with SMAD4, and translocates to the nucleus where it regulates hundreds of target genes. In the vascular wall, this pathway has a paradoxical dual role⁴⁴ paradoxical dual role
TGF-β/SMAD3 can both protect against early atherosclerosis by suppressing inflammation, and accelerate advanced disease by driving VSMC phenotype switching and fibrosis.

Research by Civelek et al.⁵⁵ Civelek et al.
demonstrating that SMAD3 and TCF21 drive opposing gene programs in smooth muscle cells established that SMAD3 promotes a synthetic/inflammatory VSMC phenotype associated with plaque instability, while TCF21 pushes toward a fibrous cap phenotype that stabilizes plaques. The rs17228212 C allele may modulate SMAD3 expression levels through intronic regulatory elements⁶⁶ intronic regulatory elements
introns frequently harbor enhancers and chromatin-accessible regions that fine-tune transcription. A 2024 study demonstrated that individuals carrying the T allele had significantly higher density of SMAD3-positive cells in carotid endarterectomy specimens⁷⁷ significantly higher density of SMAD3-positive cells in carotid endarterectomy specimens
41±6/mm² vs 25±4/mm² for C allele carriers; p<0.001, suggesting the C allele reduces SMAD3 expression in plaque tissue.

A separate but related GWAS signal at the SMAD3 locus — rs17293632, in strong LD with rs56062135⁸⁸ rs17293632, in strong LD with rs56062135
D'=0.97, r²=0.94 — has been functionally characterized: its protective T allele disrupts an AP-1 transcription factor binding site in a SMAD3 intron 1 enhancer, reducing SMAD3 expression and VSMC proliferation. The rs17228212 variant is not in strong LD with rs17293632⁹⁹ not in strong LD with rs17293632
they are independent signals at the same locus, suggesting potentially distinct regulatory mechanisms.

The Evidence

The discovery of rs17228212 came from Samani et al. in the genome-wide association study published as part of the Wellcome Trust Case Control Consortium¹⁰¹⁰ Samani et al. in the genome-wide association study published as part of the Wellcome Trust Case Control Consortium
combining 1,926 CAD cases with 2,938 controls plus 875 MI cases and 1,644 controls from the German MI Family Study, with a combined p-value of <1.3×10⁻⁶ and >80% probability of representing a true association. The combined odds ratio across discovery and replication cohorts was in the 1.21–1.33 range¹¹¹¹ 1.21–1.33 range
modest but consistent with most GWAS-identified common risk variants.

A 2024 Slovenian case-control study by Petrovic et al. enrolled 308 patients with >75% carotid stenosis and 573 controls without hemodynamically significant carotid disease¹²¹² Petrovic et al. enrolled 308 patients with >75% carotid stenosis and 573 controls without hemodynamically significant carotid disease
total n=881 unrelated Caucasians, finding the TT genotype significantly enriched in cases compared to controls (64.0% vs 56.4%). In logistic regression adjusted for age, sex, hypertension, diabetes, smoking, and hypercholesterolemia, the TT genotype had OR 4.05 (95% CI 1.10–17.75; p=0.037) vs CC¹³¹³ TT genotype had OR 4.05 (95% CI 1.10–17.75; p=0.037) vs CC
indicating CC carriers were substantially protected against advanced carotid plaque. The dominant model (any CC or CT vs TT) showed OR 3.60 (95% CI 1.15–15.45; p=0.045).

In a Spanish cohort of 1,897 rheumatoid arthritis patients¹⁴¹⁴ Spanish cohort of 1,897 rheumatoid arthritis patients
where chronic inflammation creates a high-risk cardiovascular environment, the C allele was associated with lower risk of cerebrovascular accident in anti-CCP negative patients (HR 0.36; 95% CI 0.14–0.94; p=0.038) and with lower carotid intima-media thickness (p=0.0094). This protective effect was absent in anti-CCP positive patients, suggesting autoimmune inflammatory status modifies the SMAD3 genotype effect¹⁵¹⁵ autoimmune inflammatory status modifies the SMAD3 genotype effect
inflammation may overwhelm the variant's effect on basal TGF-β signaling.

Replication has been inconsistent: studies in Pakistani¹⁶¹⁶ Pakistani
per-allele OR 1.22, p=0.19 and Iranian populations¹⁷¹⁷ Iranian populations
monomorphic, all TT found no significant associations with CAD. East Asian populations show near-zero C allele frequency (~0.07%), making the variant essentially uninformative in those groups.

The overall picture from the literature is that the C allele is more likely protective than risk-increasing for CAD and carotid atherosclerosis, consistent with the idea that lower SMAD3 expression in vascular tissue reduces VSMC proliferation and plaque progression. The original GWAS finding of C allele as a risk factor has not replicated consistently, and the mechanistic data aligns with C being protective.

Practical Actions

Given the mixed evidence, individuals with TT genotype (most common at ~56%) have no protective C allele and are at the population-average or modestly elevated risk for atherosclerotic disease mediated through TGF-β/SMAD3 signaling. This warrants attention to vascular risk factors that interact with this pathway — particularly omega-3 fatty acids, which modulate TGF-β signaling in vascular cells¹⁸¹⁸ omega-3 fatty acids, which modulate TGF-β signaling in vascular cells
EPA and DHA reduce inflammatory cytokine production and VSMC activation, and high-sensitivity CRP monitoring as an inflammation biomarker¹⁹¹⁹ high-sensitivity CRP monitoring as an inflammation biomarker
given SMAD3's role at the inflammation-fibrosis interface in atherosclerosis.

Individuals with CC genotype (~6%) carry two copies of the allele associated with lower SMAD3 expression in plaques and potentially reduced atherosclerotic progression — though the evidence does not yet support any specific supplement or pharmacologic intervention targeting this mechanism directly.

Interactions

The SMAD3 locus harbors at least two independent CAD-associated signals: rs17228212 (this variant) and rs56062135/rs17293632, which are in strong LD with each other but not with rs17228212. The rs17293632 C allele has been functionally characterized as increasing SMAD3 enhancer activity through AP-1 binding, and the protective T allele reduces SMAD3 expression in arterial smooth muscle cells. SMAD3 and TCF21²⁰²⁰ SMAD3 and TCF21
both CAD GWAS genes at separate loci have opposing effects on VSMC phenotype — SMAD3 promotes synthetic/inflammatory SMC states, while TCF21 drives fibrous differentiation. The combined genetic burden across SMAD3 and TCF21 variants may more completely characterize an individual's vascular smooth muscle cell plasticity and coronary disease risk.